TaiGen Biopharmaceuticals Holdings Limited

NT$7.81As of Sun 8 Nov 2026, 12:00 UTC
TPEx:4157Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (12.58%)
Div yield —
ROE 15.55%
Biotechnology
Beta (5Y) 0.23
PE TTM 36.90
TSR TTM (14.08%)
Mkt cap NT$5.559B
ROIC 70.00%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$8.71
11.51%
(38.26%)
Hold 5|5|1|5|0
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.14
0.14
0.15
0.14
6.92%
0.30%
7.66%
(0.24%)
RevenueNT$M
505.1
531.9
562.7
587.2
12.33%
17.81%
22.75%
22.80%
Peers (US$167.9M)
Cap (US$)
PE
184.3M
5.939x
168.3M
—
Capital
TTM
5Y
10Y
Leveragex
0.788
0.295
0.252
EBIT/Intx
5.337
0.931
0.785
Own earn%
(13.77)
(228.03)
(228.95)
Sh yield%
36.42
34.35
30.16
Owners
Insiders/Inst%
3.92
27.25
Short interest%
1.31
SBC / revenue%
5.97
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
12–17
$1 testx
0.3
Incr. ROIC%
12